BioSpace News Archive

Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology taking place at the Phoenix Convention Center from Nov.

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the first adolescent patient has been dosed in clinical trial with its second generation pan-TRK inhibitor ICP-723 at the Sun Yat-sen University Cancer Center.

Inventiva announced that AbbVie communicated during their third-quarter financial results on Friday October 28th, that they decided to stop the development of cedirogant, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.

Actinium Pharmaceuticals, Inc. announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B.

Biophytis SA publishes its key financial figures as of 30 June 2022 and announces that the audited consolidated financial statements previously published by the Company for the year ended December 31st, 2021 are being restated to correct the accounting treatment of the Kréos financing agreement signed in November 2021.

BrainChip Holdings Ltd, the world’s first commercial producer of ultra-low power neuromorphic AI IP, announces the appointment of Duy-Loan Le to its Board of Directors, as a non-executive director.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the pricing of its previously announced underwritten public offering of 6,865,672 shares of Class A common stock at a price to the public of $33.50 per share.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its Board of Directors, effective immediately.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, a privately-held, leading international pharmaceutical company, announced that the European Commission has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis.

GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced third quarter fiscal 2022 results for the period ended September 30, 2022.